Show simple item record

dc.creatorPelgrim, Teuntje A. D.
dc.creatorPhilipsen, Alexandra
dc.creatorYoung, Allan H.
dc.creatorJuruena, Mario
dc.creatorJimenez, Ester
dc.creatorVieta, Eduard
dc.creatorJukić, Marin
dc.creatorVan der Eycken, Erik
dc.creatorHeilbronner, Urs
dc.creatorMoldovan, Ramona
dc.creatorKas, Martien J. H.
dc.creatorJagesar, Raj R.
dc.creatorNöthen, Markus M.
dc.creatorHoffmann, Per
dc.creatorShomron, Noam
dc.creatorKilarski, Laura L
dc.creatorvan Amelsvoort, Thérèse
dc.creatorCampforts, Bea
dc.creatorvan Westrhenen, Roos
dc.date.accessioned2024-03-05T09:28:34Z
dc.date.available2024-03-05T09:28:34Z
dc.date.issued2024
dc.identifier.issn1424-8247
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/5548
dc.description.abstract(1) Background Pharmacological treatment for psychiatric disorders has shown to only be effective in about one-third of patients, as it is associated with frequent treatment failure, often because of side effects, and a long process of trial-and-error pharmacotherapy until an effective and tolerable treatment is found. This notion emphasizes the urgency for a personalized medicine approach in psychiatry. (2) Methods This prospective patient- and rater-blinded, randomized, controlled study will investigate the effect of dose-adjustment of antidepressants escitalopram and sertraline or antipsychotics risperidone and aripiprazole according to the latest state-of-the-art international dosing recommendations for CYP2C19 and CYP2D6 metabolizer status in patients with mood, anxiety, and psychotic disorders. A total sample of N = 2500 will be recruited at nine sites in seven countries (expected drop-out rate of 30%). Patients will be randomized to a pharmacogenetic group or a dosing-as-usual group and treated over a 24-week period with four study visits. The primary outcome is personal recovery using the Recovery Assessment Scale as assessed by the patient (RAS-DS), with secondary outcomes including clinical effects (response or symptomatic remission), side effects, general well-being, digital phenotyping, and psychosocial functioning. (3) Conclusions This is, to our knowledge, the first international, multi-center, non-industry-sponsored randomized controlled trial (RCT) that may provide insights into the effectiveness and utility of implementing pharmacogenetic-guided treatment of psychiatric disorders, and as such, results will be incorporated in already available dosing guidelines.
dc.publisherMDPI
dc.relationThe European Union’s Horizon 2020 research
dc.relationInnovation program under grant agreement No 945151 (chief principal investigator: R.v.W.; Work Package Leaders R.v.W., M.J., R.M., J.K., A.Y., M.J., J.K., N.S. and U.H.)
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcePharmaceuticals
dc.subjectpersonalized medicine
dc.subjectpharmacogenomics
dc.subjectanxiety disorders
dc.subjectbipolar disorder
dc.subjectdepressive disorders
dc.subjectmental disorders
dc.subjectprecision psychiatry
dc.subjectpsychopharmacology
dc.subjectpsychotic disorders
dc.subjectschizophrenia
dc.titleA New Intervention for Implementation of Pharmacogenetics in Psychiatry: A Description of the PSY-PGx Clinical Study
dc.typearticle
dc.rights.licenseBY
dc.citation.volume17
dc.citation.issue2
dc.citation.spage151
dc.identifier.wos001173103600001
dc.identifier.doi10.3390/ph17020151
dc.identifier.pmid38399366
dc.identifier.scopus2-s2.0-85185965017
dc.identifier.fulltexthttp://farfar.pharmacy.bg.ac.rs/bitstream/id/15637/A_New_Intervention_pub_2024.pdf
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record